Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026

FDA 510(k)-cleared next-generation diagnostic platform delivers 3x faster results with 50% less blood, setting a new standard for data-driven heart failure management. Key Highlights: Commercial Acceleration: Daxor to feature its FDA-cleared, next-generation Blood Volume Analyzer (BVA™) designed for rapid clinical adoption across hospital systems and outpatient clinics Clinical Evidence: Independent clinical investigators to present two ePosters highlighting how BVA addresses volume derangements in complex heart failure, LVAD, and total artificial heart patients On-Site Demonstrations: Daxor participating in HFSA's dedicated Device Day and exhibiting at Booth #803 in Phoenix, AZ (October 9–12, 2026) OAK RIDGE, Tenn.